Recent Quotes (30 days)

You have no recent quotes
chg | %

Knight Therapeutics Inc  

(Public, CVE:GUD)   Watch this stock  
Find more results for GUD
6.14
Delayed:   3:59PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 3.51 - 7.24
Open     -
Vol / Avg. 0.00/822,875.00
Mkt cap 138.83M
P/E     -
Div/yield     -
EPS 0.00
Shares     -
Beta     -
Inst. own     -
Nov 9, 2016
Q3 2016 KNIGHT THERAPEUTICS Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 11, 2016
Q2 2016 KNIGHT THERAPEUTICS Inc Earnings Release
Aug 11, 2016
Q2 2016 KNIGHT THERAPEUTICS Inc Earnings Call
Jun 9, 2016
KNIGHT THERAPEUTICS Inc at Jefferies Healthcare Conference
  

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 391.72% 3294.79%
Operating margin 479.65% 3569.53%
EBITD margin - -865.38%
Return on average assets 2.37% 6.02%
Return on average equity 2.39% 6.10%
Employees 14 -
CDP Score - -

Address

376 Victoria Ave Suite 220
WESTMOUNT, QC H3Z 1C3
Canada
+1-514-3401112 (Phone)
+1-514-3444675 (Fax)

Website links

Description

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company's principal business activity is developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. The Company finances other life sciences companies in Canada and internationally with the goal of earning interest income and securing product distribution rights for Canada and select international markets. It invests in life sciences venture capital funds whereby the Company earns a return similar to any other limited partner in the fund and receives preferential access to healthcare products from around the world for Canada and select international markets. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO and VEWS Vascular Early Warning System.

Officers and directors

James C. Gale Independent Chairman of the Board
Age: 65
Jonathan Ross Goodman President, Chief Executive Officer, Director
Age: 47
Jeffrey Kadanoff Chief Financial Officer
Amal Khouri Vice President - Business Development
Robert N. Lande Independent Director
Age: 52
Edward J. Schutter Independent Director
Age: 64
Sylvie Tendler Independent Director